Provided by Tiger Trade Technology Pte. Ltd.

SAB Biotherapeutics, Inc.

3.72
-0.0650-1.72%
Volume:429.34K
Turnover:1.59M
Market Cap:338.01M
PE:-2.39
High:3.76
Open:3.75
Low:3.68
Close:3.78
52wk High:5.15
52wk Low:1.85
Shares:90.99M
Float Shares:62.04M
Volume Ratio:2.31
T/O Rate:0.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5562
EPS(LYR):-0.7944
ROE:-11.27%
ROA:-33.46%
PB:1.57
PE(LYR):-4.68

Loading ...

Buy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst

TIPRANKS
·
Apr 23

SAB BIO says Phase 1 SAB-142 trial preserves C-peptide in adult type 1 diabetes

Reuters
·
Apr 22

SAB Bio Presents Additional Clinical and Mechanistic Data From SAB-142 Phase 1 Trial in Adult Patients With Established Autoimmune Type 1 Diabetes at Ids 2026

THOMSON REUTERS
·
Apr 22

SAB Biotherapeutics says SAFEGUARD trial of SAB-142 in type 1 diabetes enrolls patients

Reuters
·
Apr 15

SAB Biotherapeutics closes USD 85 million follow-on stock offering

Reuters
·
Mar 20

Press Release: SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

Dow Jones
·
Mar 20

BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies

Reuters
·
Mar 19

BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist

Reuters
·
Mar 18

SAB Biotherapeutics launches underwritten public offering of common stock and pre-funded warrants

Reuters
·
Mar 18

SAB Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Mar 18

Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC)

TIPRANKS
·
Mar 12

SAB Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 12

Craig-Hallum Sticks to Their Buy Rating for SAB Biotherapeutics (SABS)

TIPRANKS
·
Mar 11

SAB Biotherapeutics price target raised to $14 from $12 at Chardan

TIPRANKS
·
Mar 11

SAB Reports C-Peptide Preservation Signals in Type 1 Diabetes Trial

MT Newswires Live
·
Mar 11

SAB Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 10

SAB Biotherapeutics announces additional Phase 1 data for SAB-142

TIPRANKS
·
Mar 10

SAB Bio Announces Additional Phase 1 Data for SAB-142 in Adult Patients With Established Autoimmune Type 1 Diabetes

THOMSON REUTERS
·
Mar 10

SAB Biotherapeutics Inc - Safeguard Trial Enrolling Globally With Topline Data Expected 2H 2027

THOMSON REUTERS
·
Mar 10

SAB Biotherapeutics Inc - Phase 1 T1d Cohort Shows Early Signals of C-Peptide Preservation With SAB-142

THOMSON REUTERS
·
Mar 10